{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:47:42Z","timestamp":1768834062167,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000149","name":"Canadian Association of Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bpg.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T02:46:54Z","timestamp":1550544414000},"page":"101604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["IL12\/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?"],"prefix":"10.1016","volume":"38-39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2019.02.006_bib1","doi-asserted-by":"crossref","first-page":"j2505","DOI":"10.1136\/bmj.j2505","article-title":"Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease","volume":"357","author":"Cohen","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.bpg.2019.02.006_bib2","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.bpg.2019.02.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2011.04679.x","article-title":"Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy","volume":"34","author":"Danese","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.02.006_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11938-018-0175-1","article-title":"Novel therapies and treatment strategies for patients with inflammatory bowel disease","volume":"16","author":"Duijvestein","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.bpg.2019.02.006_bib5","first-page":"1","article-title":"Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease","author":"Ma","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bpg.2019.02.006_bib6","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bpg.2019.02.006_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/187152809787582507","article-title":"The IL-12 family of cytokines in infection, inflammation and autoimmune disorders","volume":"8","author":"Gee","year":"2009","journal-title":"Inflamm Allergy - Drug Targets"},{"key":"10.1016\/j.bpg.2019.02.006_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.gastro.2016.10.018","article-title":"Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/intimm\/dxn132","article-title":"IL-23 modulates CD56+\/CD3- NK cell and CD56+\/CD3+ NK-like T cell function differentially from IL-12","volume":"21","author":"van de Wetering","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.bpg.2019.02.006_bib10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1084\/jem.20101712","article-title":"IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease","volume":"208","author":"Geremia","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.bpg.2019.02.006_bib12","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bpg.2019.02.006_bib13","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe crohn's disease: real-world experience from a multicenter cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2019.02.006_bib15","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort","volume":"45","author":"Ma","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.02.006_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with crohn's disease refractory to anti-tumor necrosis factor Agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.02.006_bib17","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the treatment of refractory crohn's disease: the Spanish experience in a large multicentre open-label cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2019.02.006_bib18","article-title":"Safety and efficacy of ustekinumab induction therapy in patients with moderate to severe ulcerative colitis: results from the phase 3 unifi study","volume":"6","author":"Sands","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.bpg.2019.02.006_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.qco.0000224818.42729.67","article-title":"Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy","volume":"19","author":"Bowman","year":"2006","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.bpg.2019.02.006_bib20","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/eji.200324038","article-title":"The role of interleukin-12 in human infectious diseases: only a faint signature","volume":"33","author":"Fieschi","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bpg.2019.02.006_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1158\/1535-7163.MCT-06-0003","article-title":"Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas","volume":"5","author":"Meeran","year":"2006","journal-title":"Mol Canc Therapeut"},{"key":"10.1016\/j.bpg.2019.02.006_bib22","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpg.2019.02.006_bib23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.bpg.2019.02.006_bib24","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2019.02.006_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with crohn's disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib27","first-page":"1329","article-title":"Briakinumab for treatment of Crohn's disease: results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2019.02.006_bib28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2019.02.006_bib29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.02.006_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe crohn's disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib31","article-title":"Long-term safety in the open-label period of a phase 2a study of brazikumab, an antibody against interleukin-23","volume":"6","author":"Sands","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.bpg.2019.02.006_bib32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bpg.2019.02.006_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(18)34449-4","article-title":"Efficacy and safety of anti-interleukin-23 therapy with mirikizumab (LY3074828) in patients with moderate-to-severe ulcerative colitis in a phase 2 study","volume":"154","author":"Sandborn","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2019.02.006_bib35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib36","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib39","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.02.006_bib40","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease","author":"Schmitt","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.02.006_bib41","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib42","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.02.006_bib43","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A\u00a0phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.02.006_bib44","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2019.02.006_bib45","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with crohn's disease: results from celest","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.02.006_bib46","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.02.006_bib47","article-title":"An integrated safety data analysis across all phase II and phase III clinical programs for ustekinumab in psoriatic arthritis, Crohn's disease, and psoriasis","volume":"68","author":"Gensler","year":"2016","journal-title":"Arthritis Rheum"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169181930006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169181930006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:01:52Z","timestamp":1761498112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169181930006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":47,"alternative-id":["S152169181930006X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2019.02.006","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL12\/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101604"}}